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Abstract
Background: In the surgical treatment of intrahepatic cholangiocarcinoma (ICC), postoperative complications may
be predictive of long-term survival. This study aimed to identify an immune-nutritional index (INI) that can be used
for preoperative prediction of complications.
Patients and methods: Multi-institutional data from 316 patients with ICC who had undergone surgical resection
were retrospectively analysed, with a focus on various preoperative INIs.
Results: Severe complications (Clavien-Dindo grade III–V) were identified in 66 patients (20.8%), including Grade V
complications in 7 patients (2.2%). Comparison of areas under the receiver operating characteristic curve (AUCs)
among various INIs identified the prognostic nutritional index (PNI) as offering the highest predictive value for
severe complications (AUC = 0.609, cut-off = 50, P = 0.008). Multivariate analysis revealed PNI < 50 (odds ratio [OR] =
2.22, P = 0.013), hilar lesion (OR = 2.46, P = 0.026), and long operation time (OR = 1.003, P = 0.029) as independent risk
factors for severe complications. In comparing a high-PNI group (PNI ≥ 50, n = 142) and a low-PNI group (PNI < 50,
n = 174), the low-PNI group showed higher rates of both major complications (27% vs. 13.4%; P = 0.003) and
infectious complications (14.9% vs. 3.5%; P = 0.0021). Furthermore, median survival time and 1- and 5-year overall
survival rates were 34.2 months and 77.4 and 33.8% in the low-PNI group, respectively, and 52.4 months and 89.3
and 47.5% in the high-PNI group, respectively (P = 0.0017).
Conclusion: Preoperative PNI appears useful as an INI correlating with postoperative severe complications and as a
prognostic indicator for ICC.
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Core tip
This is the first large-scale, multicentre retrospective
study to investigate immune-nutritional indices predict-
ing postoperative complications among patients with
surgically resected intrahepatic cholangiocarcinoma
(ICC). We retrospectively examined the medical records
of 316 patients and evaluated preoperative prognostic
nutritional index (PNI), neutrophil-to-lymphocyte ratio,
lymphocyte-to-monocyte ratio, and controlling nutri-
tional status. Low PNI (PNI < 50) was an independent
predictor of severe complications and poor survival. Cli-
nicians should thus pay attention to perioperative care
for patients with ICC and low PNI.
Introduction
Intrahepatic cholangiocarcinoma (ICC) is the second
most common primary cancer of the liver, and arises
from the intrahepatic bile ducts [1, 2]. Both the inci-
dence and mortality of ICC have been increasing world-
wide [1]. ICC has an estimated 5-year survival rate of
30% [3, 4], and represents an aggressive cancer type that
can be curatively treated by complete surgical resection.
The surgical approach typically involves liver resection
with en bloc resection of regional lymph nodes. This
represents one of the most invasive surgical procedures
for the treatment of a gastrointestinal cancer. Gaya et al.
reported on postoperative complications as independent
predictors of poor long-term survival in patients with
ICC [5]. They reported that 15.6 and 26.2% of patients
developed major and minor postoperative complications,
respectively. Moreover, 3.5% of patients died within 90
days after surgery.
The tumour-node-metastasis staging system is the
standard tool for predicting prognosis in patients with
cancer. Both immune and nutritional statuses reportedly
play important roles in cancer progression and prognosis
[6, 7]. Furthermore, researchers have investigated the
associations of various parameters, including prognostic
nutritional index (PNI), neutrophil-to-lymphocyte ra-
tio (NLR), lymphocyte-to-monocyte ratio (LMR), and
Controlling Nutritional Status (CONUT) score, with
postoperative complications and prognosis in pa-
tients with cancer. More detailed investigations are
thus needed to clarify the relationship between pre-
operative immune-nutritional indices (INIs) and
postoperative complications, to allow the identifica-
tion of high-risk patients with ICC prior to radical
surgery. We therefore aimed to identify INIs predict-
ive of postoperative complications following ICC
resection. This appears to represent the first large-
scale, multicentre retrospective study to evaluate
INIs predicting postoperative complications in pa-
tients with surgically resected ICC.
Materials and methods
Patients and methods
We retrospectively examined the medical records of 415
patients with ICC who underwent curative surgical re-
section at 17 institutions in Japan between January 2000
and December 2016. These institutions comprised
Okayama University Hospital, Okayama Saiseikai
General Hospital, Hiroshima Citizens Hospital, Kochi
Health Sciences Center, Himeji Red Cross Hospital,
National Fukuyama Medical Center, Tottori Municipal
Hospital, Tenwakai Matsuda Hospital, National
Okayama Medical Center, Fukuyama City Hospital,
Himeji St. Maria Hospital, Matsuyama Municipal
Hospital, Sumitomo Besshi Hospital, Onomichi Munici-
pal Hospital, National Iwakuni Medical Center, Himeji
Central Hospital, and Kobe Red Cross Hospital. Twelve
of these institutions are board-certified training institu-
tions for the Hepatobiliary and Pancreatic Surgery
program in Japan [8]. Consequently, most patients were
recruited from qualified programs, leading to relatively
standardised operative procedures and classification of
outcomes. Subjects meeting the following criteria were
excluded: 1) non-curative (residual tumor, peritoneal
dissemination, or positive surgical margin) surgery; or 2)
lacking sufficient data about aforementioned INIs were
lacking; or 3) laparoscopic procedure. After excluding
those individuals, a total of 316 patients were included
in this study. Median patient’s follow-up period after
surgery was 27.5 months (interquartile range. 13.2–51.2
months). We examined clinicopathological characteris-
tics, surgical procedures, postoperative complications,
overall survival (OS), and PNI, NLR, LMR, and CONUT
score as preoperative INIs.
PNI was calculated using the following formula:
10 serum albumin g=dLð Þ þ 0:005
 total lymphocyte count =mm3 
NLR was determined by dividing the neutrophil count
by the lymphocyte count. In contrast, LMR was deter-
mined by dividing the lymphocyte count by the mono-
cyte count. CONUT score was calculated from serum
albumin concentration, total cholesterol concentration,
and total peripheral lymphocyte count as previously
described [9]. Postoperative complications were defined
as any in-hospital or 90-day postoperative complications,
graded based on the Clavien-Dindo classification [10]. If
a case displayed more than one complication, the com-
plication with the highest grade was used. Infectious
complications were categorised according to the Centers
for Disease Control Classification System [11]. This
study was approved by the Okayama University Hospital
Institutional Ethics Board. The need for written
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informed consent was waived because of the retrospect-
ive design.
Statistical analysis
Clinical variables were compared using the Mann-
Whitney U test for continuous data and Pearson’s cor-
relation coefficient for categorical data. Continuous vari-
ables are presented as median and interquartile range.
Values of P< 0.05 were considered significant. The pre-
dictive value of potential factors for severe complications
(defined as grade III–V complications) was assessed by
the corresponding area under the receiver operating
characteristic curve (AUC). Youden index was utilised to
choose optimal cut-off values, set as the value maximis-
ing the sum of sensitivity and specificity. AUCs were
compared with each other in a nonparametric approach
using the theory for generalised U-statistics to generate
an estimated covariance matrix [12]. With regard to sur-
vival analysis, survival curves were estimated using
Kaplan-Meier methods, and differences in survival were
evaluated with the log-rank test and Wilcoxon test. We
used logistic regression analysis to identify risk factors
for severe complications. For this analysis, clinical vari-
ables showing values of P< 0.05 in univariate analyses
were entered into the multivariate analysis. Odds ratios
(ORs) and 95% confidence intervals (CIs) were calcu-
lated. All statistical analyses were performed using JMP
version 14 (SAS Institute, Cary, NC, USA).
Results
Postoperative complications (Clavien-Dindo classification)
All postoperative complications are summarised in
Table 1. Postoperative complications occurred in 111
patients (35.2%), of whom 59 patients (18.6%) experi-
enced postoperative complications of grade III–IV. The
leading cause of complications was bile leakage (n=37,
11.7%), followed by intra-abdominal abscess (n=16,
5.1%), and delayed gastric emptying (n=15, 4.7%) due to
dissection of the lymphatic station around the lesser
curvature of the stomach in cases of left-side




Grade of surgical complicationa
None I-II III-IV V
No complications - Grade II (%) 250 (79.1%) 205 (64.8%) 45 (14.2%)
Grade III-V (%) 66 (20.8%) 59 (18.6%) 7 (2.2%)
Total no. of complications (%) 111 (35.2%)
Cardiovascular
heart failure 2 (0.6%) 1 (0.3%) 1 (0.3%)
deep venous thrombosis 2 (0.6%) 2 (0.6%)
Pulmonary
pleural effusion 4 (1.3%) 2 (0.6%) 2 (0.6%)
pneumonia 1 (0.3%) 1 (0.3%)
Gastrointestinal
gastrointestinal hemorrhage 4 (1.3%) 2 (0.6%) 1 (0.3%) 1 (0.3%)
delayed gastric empting 15 (4.7%) 14 (4.4%) 1 (0.3%)
intestinal obstruction 5 (1.6%) 2 (0.6%) 3 (0.9%)
Surgical site infections
superficial-deep wound 8 (2.5%) 7 (2.2%) 1 (0.3%)
intra-abdominal abscess 16 (5.1%) 1 (0.3%) 14 (4.4%) 1 (0.3%)
Liver/Biliary
bile leak 37 (11.7%) 6 (1.9%) 31 (9.8%)
portal vein thrombosis 4 (1.3%) 4 (1.3%)
anastomotic leak 1 (0.3%) 1 (0.3%)
Others
intra-abdominal hemorrhage 3 (0.9%) 1 (0.3%) 1 (0.3%) 1 (0.3%)
sepsis 3 (0.9%) 2 (0.6%) 1 (0.3%)
ascites 6 (1.9%) 4 (1.3%) 2 (0.6%)
aClavien-Dindo classification
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predominant ICC [13]. In addition, 7 patients (2.2%)
died due to Grade V complications, comprising portal
vein thrombosis (n=4), intra-abdominal abscess (n=1),
gastrointestinal haemorrhage (n=1), and intra-abdominal
haemorrhage after rupture of pseudo-aneurysm (n=1).
The most common infectious complication was surgical
site infection (n=24, including 16 cases of intra-
abdominal abscess), followed by bloodstream infection
(n=3), intra-abdominal haemorrhage due to abscess(n=
3), and pneumonia (n=1). Of these, severe complications
(Clavien-Dindo classification grades III-V) were seen in
19 patients, with intra-abdominal abscess being the lead-
ing cause.
Predictive values of INIs for postoperative complications
We plotted the receiver operating characteristic curves
for PNI, NLR, LMR, and CONUT score to investigate
the ability of INIs to predict severe complications. PNI
showed the highest predictive value (AUC=0.6094,
95%CI=0.5315–0.6822, P=0.008), followed by LMR
(AUC=0.537, 95%CI=0.455–0.616, P=0.003), CONUT
score (AUC=0.518, 95%CI=0.432–0.594, P< 0.001), and
NLR (AUC=0.478, 95%CI=0.399–0.558, P< 0.001). With
PNI, the cut-off was calculated as 50, corresponding to
the maximal Youden index (Fig. 1). Comparisons of each
AUC using a nonparametric approach revealed PNI as
the most suitable parameter for predicting postoperative
complications (Table 2).
Relationships between PNI and clinicopathological
characteristics
Patients were divided into two groups: a high-PNI group
(PNI ≥ 50, n=142); and a low-PNI group (PNI < 50, n=
174). Table 3 outlines the clinicopathological character-
istics of the two groups. The low-PNI group showed
significantly older age, lower BMI, lower lymphocyte
count, lower albumin concentration, longer prothrombin
time, lower total cholesterol concentration, higher C-
reactive protein concentration, and higher concentration
of cancer antigen 19–9. In terms of cancer localisation,
hilar-type ICC predominated in the low-PNI group. As a
result, bile duct resection was required at the time of
surgery more frequently than in the high-PNI group.
With regard to postoperative complications, frequency
of severe (grade III–V) complications was higher in the
low-PNI group than in the high-PNI group (P=0.003).
Postoperative mortality (grade V) was seen in 7 cases
(4%) in the low-PNI group and in 1 case (0.7%) in the
high-PNI group. Infectious complications characterised
by surgical site infection (including superficial and
organ/space abscess), bloodstream infection, and pneu-
monia were more frequently in the low-PNI group
(14.9%) than in the high-PNI group (3.5%; P=0.021). On
the other hand, frequencies of non-infectious complica-
tions characterised by other events were comparable be-
tween the low-PNI group (25.9%) and the high-PNI
group (24.6%) (Table 3, Fig. 2a). For severe complica-
tions (n=66), the frequency of infectious complications
was 36.2% in the low-PNI group, but only 10.5% in the
high-PNI group (P=0.0372) (Fig. 2b). Adjuvant chemo-
therapy resulted in a significantly lower induction rate in
the low-PNI group (32.7%) than in the high-PNI group
(45.7%; P=0.0181) (Table 3).
Fig. 1 Receiver operating characteristic curves for immune-
nutritional indices related to severe postoperative complications
Table 2 Comparisons of each AUC for predicting postoperative complications
Variables difference Standard error 95%CI ×2 P-value
PNI vs NLR 0.131 0.043 0.045 0.215 9.061 0.003
PNI vs LMR 0.073 0.039 −0.004 0.149 3.415 0.064
PNI vs CONUTS 0.095 0.028 0.040 0.151 11.394 < 0.001
LMR vs NLR 0.058 0.042 −0.025 0.141 1.888 0.169
LMR vs CONUTS 0.023 0.044 −0.064 0.109 0.278 0.600
NLR vs CONUTS −0.035 0.045 −0.123 0.052 0.617 0.431
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Table 3 Clinicopathological characteristics of the low PNI group and the high PNI group
Variables All patients
(n=316)
Low PNI group High PNI group P-
value*PNI < 50 (n=174) PNI ≥ 50 (n=142)
Preoperative factors
Male, n (%) 187 (59.1%) 100 (57.5%) 87 (61.3%) 0.495
Age (years), median (IQR) 71 (63–76) 72.5 (66–79) 68 (62–74) 0.002
BMI, median (IQR) 22.1 (20.0–24.8) 22.0 (19.2–24.0) 22.8 (21.0–25.2) 0.048
Lymphocytes (/ul), median (IQR) 1560 (1190-1931) 1328 (1058-1625) 1894 (1508-2332) <.0001
Neutrophils (/ul), median (IQR) 3652 (2834-4908) 3692 (2781-5027) 3634 (2920-4474) 0.759
Monocytes (/ul), median (IQR) 342 (277–440) 342 (270–436) 342 (281–442) 0.669
Platelet count (104/uL), median (IQR) 19.9 (15.4–24.5) 19.9 (14.5–25.4) 20.1 (16.8–23.6) 0.827
Total Bilirubin (mg/dl), median (IQR) 0.7 (0.5–0.9) 0.7 (0.50–0.90) 0.7 (0.54–0.90) 0.698
Albumin (mg/dl), median (IQR) 4.1 (3.8–4.4) 3.8 (3.5–4.1) 4.3 (4.3–4.6) <0.001
AST (U/L), median (IQR) 29 (22–39) 29 (22–42) 29 (23–37) 0.978
ALT (U/L), median (IQR) 25 (16–39) 24 (15–39) 27 (18–38) 0.142
Prothrombin time (INR), median (IQR) 1.03 (0.97–1.10) 1.04 (1.0–1.13) 1.01 (0.95–1.07) <.0001
Total Cholesterol (mg/dL), median (IQR) 185 (166–211) 180 (156–206) 194 (173–220) 0.015
HBV-Ag, n (%) 18 (5.7%) 11 (6.3%) 7 (4.9%) 0.595
HCV-Ab, n (%) 47 (14.9%) 29 (16.7%) 18 (12.7%) 0.321
CRP (mg/dl), median (IQR) 0.2 (0.09–0.70) 0.3 (0.10–1.04) 0.16 (0.08–0.34) 0.010
Preoperative chemotherapy, n (%) 7 (2.2%) 6 (3.5%) 1 (0.7%) 0.099
Tumor factor
Morphology, n (%)
Mass-forming (MF) 234 (74.5%) 123 (71.1%) 111 (78.7%) 0.260
Periductal-infiltrating (PI) 30 (9.6%) 16 (9.3%) 14 (9.9%)
MF+PI 34 (10.8%) 23 (13.3%) 11 (7.8%)
Intraductal Growth 16 (5.1%) 11 (6.3%) 5 (3.6%)
Tumor size (cm), median (IQR) 4.0 (2.8–6.5) 4.5 (3.0–7.0) 4.0 (2.5–6.0) 0.253
Multi-nodular, n (%) 63 (19.9%) 35 (20.1%) 28 (19.7%) 0.930
Localization, n (%)
Hilar 111 (35.1%) 72 (41.4%) 39 (27.5%) 0.010
Peripheral 205 (64.9%) 102 (58.6%) 103 (72.5%)
CEA (ng/ml), median (IQR) 2.90 (1.80–5.87) 3.1 (2.0–7.2) 2.8 (1.6–4.7) 0.323
CA19–9 (U/ml), median (IQR) 39.4 (14.3–246.9) 52.1 (15.8–356.2) 26.3 (14.1–127.9) 0.024
Operative factors
Major hepatectomy, n (%) 222 (70.3%) 128 (73.5%) 94 (66.2%) 0.154
Type of hepatectomy, n (%)
Segmentectomy/Sub-segmentectomy 82 (25.9%) 39 (22.4%) 43 (30.3%) 0.196
Hemihepatectomy 221 (69.9%) 126 (72.4%) 95 (66.9%)
Trisectionectomy 13 (4.1%) 9 (5.2%) 4 (2.82%)
Lymphnode dissection, n (%) 218 (68.9%) 117 (67.2%) 101 (71.1%) 0.458
Bile duct resection, n (%) 82 (25.9%) 53 (30.4%) 29 (20.4%) 0.043
Vascular reconstruction**, n (%) 24 (7.5%) 16 (9.2%) 8 (5.6%) 0.235
Blood loss (ml), median (IQR) 670 (350–1208) 780 (380–1190) 640 (304–1250) 0.499
Operation time (min), median (IQR) 348 (270–448) 354 (271–465) 333 (264–420) 0.228
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Multivariate analysis of risk factors for severe
complications
We conducted logistic regression analysis to exam-
ine risk factors for major postoperative complica-
tions (Table 4). In uni- and multivariate analyses,
PNI < 50 (OR=2.22, 95%CI=1.18–4.20, P=0.013),
hilar-type ICC (OR=2.46, 95%CI=1.11–5.45, P=
0.026), and longer operation time (OR=1.003,
95%CI=1.000–1.005, P=0.029) were revealed as inde-
pendent risk factors for severe complications. No
other preoperative parameters, pathological factors
including vascular invasion, lymph node metastasis
and differentiation, or operative factors had any pre-
dictive impact on the occurrence of severe postoper-
ative complications. In subgroup analysis stratified
by tumor location and bile duct resection, major
postoperative morbidity in hilar-type ICC was higher
in patients with PNI < 50 than in those with PNI ≥
50 (Supplementary Fig. 1).
Prognostic impact of PNI and postoperative
complications on survival after surgery
In survival analyses, median survival time (MST) and 1-
and 5-year OS rates after surgery were 42.3 months and
82.9 and 40.4%, respectively, for the total patient cohort.
In addition, 1- and 5-year recurrence-free survival rates
were 59.5 and 29.3%, respectively (Supplementary Fig. 2a,
b). Patients with severe (grade III–V) complications
showed worse outcomes than patients with grade 0–II
complications (MST: 28.0 months vs. 47.7 months; P=
0.0059) (Fig. 3a). MST was 34.2 months in the low-PNI
group, and 52.4 months in the high-PNI group (P=
0.0017) (Fig. 3b). In subgroup analysis for the low-PNI
group, severe (grade III–V) complications were associ-
ated with worse short-term outcomes than grade 0–II
complications, as in the overall analysis (Fig. 3c). On the
other hand, in subgroup analysis for the high-PNI group,
grade of complication did not have any impact on short-
or long-term outcomes. In other words, patients with
Table 3 Clinicopathological characteristics of the low PNI group and the high PNI group (Continued)
Variables All patients
(n=316)
Low PNI group High PNI group P-
value*PNI < 50 (n=174) PNI ≥ 50 (n=142)
Pathological factors
Serosa invasion, n (%) 112 (35.4%) 58 (33.3%) 54 (38.0%) 0.386
Vascular invasion, n(%) 160 (50.6%) 87 (50.0%) 73 (51.4%) 0.947
Lymph node metastasis, n(%) 86 (27.2%) 47 (27.0%) 39 (27.5%) 0.528
Differentiation, n (%) 0.221
Well 66 (20.9%) 37 (21.3%) 29 (20.4%)
Moderate 167 (52.9%) 84 (48.3%) 83 (58.4%)
Poorly 58 (18.4%) 36 (20.7%) 22 (15.5%)
Un-classified 25 (7.9%) 17 (8.7%) 8 (5.6%)
Background liver, n (%) 0.302
Normal 234 (74.0%) 123 (70.7%) 111 (78.2%)
Hepatitis 60 (19.0%) 38 (21.8%) 22 (15.5%)
Fibrosis 22 (7.0%) 13 (7.5%) 9 (6.3%)
Post-operative factors
Clavien-Dindo classification, n (%) 0.019
none 205 (64.9%) 103 (59.2%) 102 (71.8%)
Grade I-II 45 (14.2%) 24 (13.8%) 21 (14.8%)
Grade III-IV 58 (18.4%) 40 (23.0%) 18 (12.7%)
Grade V 8 (2.5%) 7 (4.0%) 1 (0.7%)
All Complication. CD-Grade I-V 111 (35.1%) 71 (40.8%) 40 (28.2%) 0.019
All Complication. CD-Grade III-V 66 (20.9%) 47 (27.0%) 19 (13.4%) 0.003
Infectious Complication. CD-Grade I-V 31 (9.8%) 26 (14.9%) 5 (3.5%) 0.002
Infectious Complication. CD-Grade IIII-V 19 (6.0%) 17 (36.2%) *** 2 (10.5%) *** 0.037
Adjuvant chemotherapy, n (%) 122 (38.6%) 57 (32.7%) 65 (45.7%) 0.018
* Low-PNI group vs High-PNI group
** reconstruction of portal vein or hepatic artery or hepatic vein or inferior vene cava
*** proportion in complicated cases
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high PNI could be expected to overcome severe compli-
cations and show a prognosis comparable to that of an
uncomplicated case (Fig. 3d). Recurrence-free survival
showed a similar trend to the survival analysis for PNI
and severe complications (Supplementary Fig. 2c, d).
Furthermore, in the subgroup analysis of the patients
with and without adjuvant chemotherapy, the low-PNI
group showed worse outcomes than the high-PNI group,
independent from adjuvant setting (Fig. 4a,b).
Discussion
Surgical resection is the only curative treatment option
for patients with ICC, but rates of morbidity and mortal-
ity remain high. Even with curative resection, patients
who experience postoperative complications display a
poor prognosis [5]. Identification of parameters to effect-
ively predict postoperative complications prior to sur-
gery is thus a critical issue. The present examination of
preoperative INIs identified PNI as a useful predictive
marker to distinguish high-risk patients with ICC before
surgery.
PNI is a widely used systemic inflammation-based
prognostic score, simply calculated based on the total
lymphocyte count and the concentration of serum albu-
min in peripheral blood. Both parameters are normally
analysed during preoperative examinations [14, 15].
While albumin is the most studied value associated with
nutritional status, the lymphocyte count reflects the
immune status of a patient. PNI thus represents both
the immune and nutritional statuses of the patient. Mal-
nutrition is closely associated with a high risk of postop-
erative complications [16]. Low PNI has been considered
a predictor of postoperative complications for surgeries
involving the gastrointestinal tract [17, 18]. A low PNI
has recently been reported as a negative prognostic fac-
tor for various types of cancers [14, 15, 17, 19]. However,
this value has not been well investigated for patients
with ICC. Özgür et al. first reported PNI < 40 as an inde-
pendent and negative prognostic factor for patients with
ICC who undergo curative surgical resection [20]. A low
preoperative PNI was associated with a poor or undiffer-
entiated ICC phenotype and advanced tumour stage
(T2–T4) [20]. Patients with PNI < 50 experienced sig-
nificantly worse prognosis than those with a higher PNI.
Several reports have been published on INIs in pa-
tients with ICC. Miyata et al. reported on the prognostic
impact of CONUT score in patients with ICC [21]. A
high CONUT score was identified as an independent
predictor of poor prognosis, but was not associated with
postoperative complications. Gomes et al. reported a
high preoperative NLR as a predictor of poorer disease-
free survival, associated with tumour aggressiveness
characterised by large tumour size, satellite lesions,
microvascular invasion, and lymph node involvement
[22]. Lin et al. reported on the association between an
elevated NLR and poor anti-tumour immunity and low
Fig. 2 a. Frequency of postoperative infectious complications in all patients (n=316). b. Frequency of postoperative infectious complications in
patients with severe complications (n=66)
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density of tumour-infiltrating CD3+ T cells. NLR could
thus represent a marker of poor prognosis for patients
with ICC [23].
We classified low- and high-PNI groups on the basis
of a cut-off of 50, set for the receiver operating charac-
teristic curve analysis. Other reports have suggested a
PNI cut-off between 40 and 50, consistent with the value
used in the present study [24]. A low PNI predicts not
only postoperative complications, but also poor survival.
Nonetheless, severe complications themselves did not
represent a significant predictor of poor long-term sur-
vival (Fig. 3a). The association between PNI and nutri-
tional and immune statuses might reflect tumour
progression and aggressiveness through the lymphocyte
count and albumin level.
Recent studies have reported that postoperative com-
plications depend on liver function reserve and peri-
operative nutritional status [25–29]. Perioperative
nutritional supplementation may thus reduce the risk of
postoperative complications and shorten the duration of
hospitalisation for patients with cancer requiring liver
resection [30–32]. Hsieh et al. reported that postopera-
tive nutritional support could contribute to the reduc-
tion of pulmonary complications, recovery of liver
function, and shortened duration of hospitalisation
among adult liver donors [33]. In addition, with high-
Table 4 Logistic regression analysis to examine risk factors for major postoperative complications
Variables Univariate analysis Multivariate analysis
Odds ratio 95% C.I. P-value Odds ratio 95% C.I. P-value
Preoperative factors
Age: ≥80 vs < 80 (years) 1.965 1.009 3.828 0.046 1.575 0.752 3.298 0.228
BMI 0.959 0.886 1.037 0.291
Platelet count (104/uL) 1.016 0.981 1.051 0.370
Total Bilirubin (mg/dl) 1.062 0.863 1.309 0.566
PNI: < 50 vs ≥ 50 2.395 1.331 4.312 0.002 2.072 1.143 3.961 0.027
AST (U/L) 1.001 0.998 1.005 0.308
ALT (U/L) 1.003 0.998 1.009 0.183
Prothrombin time (INR) 1.106 0.184 6.623 0.912
Total Cholesterol (mg/dL) 1.001 0.995 1.006 0.717
CRP (mg/dl) 1.082 0.970 1.207 0.162
Preoperative chemotherapy 2.928 0.639 13.42 0.167
Tumor factor
Morphology: Mass-forming vs the other type 0.806 0.440 1.479 0.487
Tumor size (cm) 1.049 0.957 1.151 0.298
Multi-nodular 1.382 0.724 2.637 0.326
Localization: Hilar vs Peripheral 2.523 1.151 5.530 0.020 2.548 1.143 5.683 0.022
CEA (ng/ml) 1.003 0.992 1.013 0.608
CA19–9 (U/ml) 1.000 0.999 1.000 0.827
Vascular invasion* 1.172 0.680 2.020 0.566
Lymph node metastasis 1.122 0.579 2.171 0.732
Tumor differentiation: mod/por vs well 1.662 0.889 3.111 0.112
Operative factors
Major hepatectomy vs Minor hepatectomy 1.570 0.832 2.962 0.153
Lymph node dissection 1.254 0.686 2.294 0.460
Bile duct resection 3.456 1.948 6.129 0.001 1.135 0.491 2.625 0.767
Vascular reconstruction** 2.473 1.030 5.937 0.042 1.061 0.393 2.870 0.906
Blood loss (ml) 1.001 1.000 1.001 0.032 1.000 0.999 1.000 0.612
Operation time (min) 1.004 1.002 1.006 0.001 1.003 1.000 1.006 0.026
*vascular invasion: pathologically diagnosed as invasion to portal vein, hepatic artery, hepatic vein, and inferior vena cava
**reconstruction including portal vein, hepatic artery, hepatic vein, and inferior vena cava
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risk hepatectomy for hepato-biliary cancer, synbiotics re-
portedly contribute to reductions in postoperative infec-
tious complications [34]. Such beneficial effects would
presumably involve correction of intestinal microbial im-
balances induced by surgical stress. Furthermore, nutri-
tional intervention could improve prognosis through
improvements in the tolerance of patients for chemo-
therapy and surgical feasibility [30, 35].
In addition to the predictive value of postoperative
complications, PNI was indicated as a potential prognos-
tic indicator. Adjuvant chemotherapy could provide
potential survival benefits in subgroups of patients
exhibiting increased risk, such as patients with ICC
showing advanced tumours or positive lymph node me-
tastasis [36, 37]. Our results suggest that induction rates
for adjuvant chemotherapy are reliant on PNI and post-
operative complications. This may be one reason why
low PNI and postoperative complications contribute to
worsened oncological outcomes. However, in terms of
the presence or absence of adjuvant chemotherapy, the
prognosis of PNI< 50 was poor and could be considered
an independent prognostic factor. Given the limited effi-
cacy of surgery alone, multidisciplinary treatment with
an appropriate combination of chemotherapy appears
Fig. 3 a. Kaplan-Meier curves for postoperative overall survival, stratified by grade of postoperative complications. b. Kaplan-Meier curves for
postoperative overall survival, stratified by PNI. c. Kaplan-Meier curves for postoperative overall survival, stratified by grade of postoperative
complications in the low-PNI group. d. Kaplan-Meier curves for postoperative overall survival, stratified by grade of postoperative complications in
the high-PNI group
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important for ICC. Various conditions result in the def-
inition of ‘not optimally resectable’ cases with borderline
disease; in such case, preoperative chemotherapy should
be considered rather than up-front surgery with or with-
out adjuvant chemotherapy. PNI could be useful in
selecting patients for whom such preoperative chemo-
therapy, as well as nutritional therapy interventions, may
hold promise.
Limitations
As this study deliberately selected patients who had
undergone curative surgical resection for ICC, we might
have excluded patients with advanced ICC who did not
undergo surgery because of tumour aggressiveness. The
PNI in such patients would be expected to be low.
Conclusions
Preoperative PNI can be used both as a predictive
marker for the risk of severe postoperative complications
and as a prognostic marker. PNI could reflect potential
cancer progression that is difficult to determine using
conventional diagnostic methods. Adequate nutritional
intervention for patients with low PNI in the periopera-
tive phase could contribute to further improvements in
surgical outcomes and survival for patients with ICC.
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